Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 4.9% After Insider Selling

Enliven Therapeutics, Inc. (NASDAQ:ELVN) dropped 4.9% during mid-day trading on Tuesday after an insider sold shares in the company. The stock traded as low as $18.61 and last traded at $18.73. 40,658 shares traded hands during mid-day trading, a decline of 85% from the average daily volume of 275,231 shares. The stock had previously closed at $19.68.

Specifically, CFO Benjamin Hohl sold 3,250 shares of the firm’s stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $21.33, for a total transaction of $69,322.50. Following the transaction, the chief financial officer now directly owns 23,000 shares in the company, valued at $490,590. This trade represents a 12.38 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Analyst Ratings Changes

Several brokerages have weighed in on ELVN. BTIG Research started coverage on Enliven Therapeutics in a research report on Friday, December 13th. They issued a “buy” rating and a $42.00 price objective for the company. HC Wainwright upped their price target on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the company a “buy” rating in a report on Friday, March 21st. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $38.75.

Enliven Therapeutics Trading Down 4.1 %

The firm has a market cap of $925.20 million, a PE ratio of -9.94 and a beta of 1.04. The firm has a fifty day simple moving average of $21.18 and a two-hundred day simple moving average of $23.70.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. Equities analysts expect that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enliven Therapeutics

Large investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC raised its stake in Enliven Therapeutics by 230.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock worth $36,000 after buying an additional 1,114 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Enliven Therapeutics in the 4th quarter worth approximately $97,000. BNP Paribas Financial Markets purchased a new position in shares of Enliven Therapeutics in the 4th quarter valued at approximately $112,000. ExodusPoint Capital Management LP bought a new stake in shares of Enliven Therapeutics during the fourth quarter valued at approximately $200,000. Finally, Brevan Howard Capital Management LP purchased a new stake in Enliven Therapeutics in the fourth quarter worth $228,000. Institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.